# ANRO catalysts: Alto Neuroscience, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/anro/catalysts

> Alto Neuroscience, Inc. (ANRO) has 11 upcoming catalysts. The next is the ALTO-300 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Alto Neuroscience, Inc. |
| Ticker | ANRO (NYSE) |
| SEC CIK | 1999480 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/anro |

## Cash runway

Cash $319.3M as of 2026-09-30; quarterly burn $20.8M; about 46.2 months of runway at that rate (XBRL company facts, accession 0001999480-26-000031).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [ALTO-100 topline data readout](https://sec-api.dev/pdufa/alto-100) | ANRO |  | completed, negative | "We have not yet succeeded and may not succeed in demonstrating efficacy for any product candidates in clinical trials (e.g., we reported negative topline results in October 2024 with regard to our Phase 2b trial of ALTO-100 in MDD) or in obtaining marketing approval thereafter." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/alto-20251231.htm)) |
| November 12, 2024 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/exhibit991-earningsrelease.htm)) |
| 1H 2025 | [Agomelatine topline data readout](https://sec-api.dev/pdufa/agomelatine) | ANRO | anhedonia - | scheduled | "- Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/exhibit991-earningsrelease.htm)) |
| Feb 2025 | [Alto Neuroscience, Inc. interim data readout](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed, positive | "The final analysis sample is based on the favorable outcome from the interim analysis announced in February 2025, which resulted in a recommendation to continue the study and increase the biomarker positive sample by approximately 50 subjects." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/exhibit991-earningsrelease.htm)) |
| March 17, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/exhibit991-earningsrelease.htm)) |
| Q2 2025 | [ALTO-203 topline data readout](https://sec-api.dev/pdufa/alto-203) | ANRO |  | scheduled | "- Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/exhibit991-earningsrelease.htm)) |
| May 13, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/exhibit991-earningsrelease.htm)) |
| 2H 2025 | [Alto Neuroscience, Inc. topline data readout](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | scheduled | "•Enrollment remains ongoing in the Phase 2 POC trial in CIAS, with topline data expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/exhibit991-earningsrelease.htm)) |
| 2H 2025 | [ALTO-101 topline data readout](https://sec-api.dev/pdufa/alto-101) | ANRO |  | scheduled | "ALTO-101: Enrollment is ongoing in Phase 2 POC CIAS trial; topline data expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/exhibit991-earningsrelease.htm)) |
| August 12, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/exhibit991-earningsrelease.htm)) |
| November 12, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/exhibit991-earningsrelease.htm)) |
| 1H 2026 | [ALTO-207 trial start](https://sec-api.dev/pdufa/alto-207) | ANRO | treatment resistant depression | scheduled | "Alto's most advanced and differentiated program, ALTO-207, remains on track to initiate a Phase 2b clinical trial in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/tm2610746d1_ex99-1.htm)) |
| Q1 2026 | [Alto Neuroscience, Inc. topline data readout](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | scheduled | "•Enrollment remains ongoing in the Phase 2 POC trial in CIAS, with topline data expected in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/exhibit991-earningsrelease.htm)) |
| Q1 2026 | [ALTO-101 topline data readout](https://sec-api.dev/pdufa/alto-101) | ANRO |  | scheduled | "The Company expects to report topline data from the trial around the end of the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/exhibit991-earningsrelease.htm)) |
| February 2026 | [ALTO-101 primary completion](https://sec-api.dev/pdufa/alto-101) | ANRO | Schizophrenia; Cognitive Impairment | delayed | "NCT06502964 (Study of ALTO-101 in Patients With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-02 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06502964)) |
| March 16, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/exhibit991-earningsrelease.htm)) |
| mid-2026 | [Alto Neuroscience, Inc. topline data readout](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | scheduled | "•Topline data from the double-blind, placebo-controlled, randomized Phase 2b trial is expected in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/exhibit991-earningsrelease.htm)) |
| mid-2026 | [Agomelatine interim data readout](https://sec-api.dev/pdufa/agomelatine) | ANRO |  | scheduled | "- Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/exhibit991-earningsrelease.htm)) |
| mid-2026 | [Ondif (ondansetron) trial start](https://sec-api.dev/pdufa/ondansetron) | ANRO |  | scheduled | "Leveraging our targeted biomarker approach to stratify for TRD patients most likely to respond to treatment, we look forward to building on the positive Phase 2a results and initiating a Phase 2b trial, with a potentially pivotal design, by mid-2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/exhibit991-pressrelease.htm)) |
| mid-2026 | [Agomelatine topline data readout](https://sec-api.dev/pdufa/agomelatine) | ANRO |  | scheduled | "- Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/exhibit991-earningsrelease.htm)) |
| Apr 2026 | [ALTO-207 trial start](https://sec-api.dev/pdufa/alto-207) | ANRO |  | completed | "•In April 2026, Alto initiated a randomized, double-blind, placebo-controlled Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD who have experienced between two and five prior treatment failures and continue to have moderate-to-severe depression symptoms." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/exhibit991-earningsrelease.htm)) |
| May 13, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/exhibit991-earningsrelease.htm)) |
| 2H 2026 | [Alto Neuroscience, Inc. topline data readout](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | scheduled | "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000025/alto-20241231.htm)) |
| 2H 2026 | [ALTO-100 topline data readout](https://sec-api.dev/pdufa/alto-100) | ANRO |  | scheduled | "The Phase 2b trial of ALTO-100 in Bipolar Depression (BPD) is also ongoing, with topline data anticipated in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/exhibit991-earningsrelease.htm)) |
| August 12, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/exhibit991-earningsrelease.htm)) |
| November 10, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000030/exhibit991-earningsrelease.htm)) |
| December 2026 | [ALTO-300 primary completion](https://sec-api.dev/pdufa/alto-300) | ANRO | Major Depressive Disorder | scheduled | "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05922878)) |
| Dec 2026 to Mar 2027 | [ALTO-300 topline data readout](https://sec-api.dev/pdufa/alto-300) | ANRO | Major Depressive Disorder | scheduled | "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05922878)) |
| early 2027 | [ALTO-207 trial start](https://sec-api.dev/pdufa/alto-207) | ANRO |  | scheduled | "•PACE-2 Trial (Phase 3 adjunctive TRD trial): Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027, following alignment with the FDA on the planned trial design." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/exhibit991-earningsrelease.htm)) |
| 1H 2027 | [Agomelatine topline data readout](https://sec-api.dev/pdufa/agomelatine) | ANRO |  | scheduled | "•Topline data are expected in 1H 2027 for ALTO-300 and mid-2027 for ALTO-100." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000030/exhibit991-earningsrelease.htm)) |
| 2H 2027 | [Alto Neuroscience, Inc. topline data readout](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | scheduled | "The Company expects to report topline data from the trial in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000031/alto-20260930.htm)) |
| 2H 2027 | [ALTO-207 trial start](https://sec-api.dev/pdufa/alto-207) | ANRO |  | scheduled | "In July 2026 we announced plans to further accelerate the development of ALTO-207, and we expect to initiate a monotherapy Phase 3 trial in patients with TRD in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000031/alto-20260930.htm)) |
| September 2027 | [ALTO-100 primary completion](https://sec-api.dev/pdufa/alto-100) | ANRO | Bipolar Disorder I or II With a Major Depressive Episode | scheduled | "NCT06656416 (ALTO-100 in Bipolar Disorder With Depression (BD-D)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06656416)) |
| Sep to Dec 2027 | [ALTO-100 topline data readout](https://sec-api.dev/pdufa/alto-100) | ANRO | Bipolar Disorder I or II With a Major Depressive Episode | scheduled | "NCT06656416 (ALTO-100 in Bipolar Disorder With Depression (BD-D)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06656416)) |
| November 2027 | [ALTO-207 primary completion](https://sec-api.dev/pdufa/alto-207) | ANRO | Treatment-resistant Depression (TRD) | scheduled | "NCT07553637 (ALTO-207 in Adults With Treatment-resistant Depression (TRD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553637)) |
| Nov 2027 to Feb 2028 | [ALTO-207 topline data readout](https://sec-api.dev/pdufa/alto-207) | ANRO | Treatment-resistant Depression (TRD) | scheduled | "NCT07553637 (ALTO-207 in Adults With Treatment-resistant Depression (TRD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553637)) |
| 2029 | [ALTO-207 NDA/BLA submission](https://sec-api.dev/pdufa/alto-207) | ANRO |  | scheduled | "- Closed $120 million PIPE in March 2026; cash balance of approximately $264 million expected to fund planned operations through 2029, including a potential NDA submission for ALTO-207 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/exhibit991-earningsrelease.htm)) |

## Drugs

- [Agomelatine](https://sec-api.dev/pdufa/agomelatine): anhedonia -
- [ALTO-100](https://sec-api.dev/pdufa/alto-100): Bipolar Disorder I or II With a Major Depressive Episode
- [ALTO-101](https://sec-api.dev/pdufa/alto-101): Schizophrenia
- [ALTO-203](https://sec-api.dev/pdufa/alto-203): 
- [ALTO-207](https://sec-api.dev/pdufa/alto-207): treatment resistant depression, Treatment-resistant Depression (TRD)
- [ALTO-300](https://sec-api.dev/pdufa/alto-300): Major Depressive Disorder
- [Ondif (ondansetron)](https://sec-api.dev/pdufa/ondansetron): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/anro/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ANRO catalysts: Alto Neuroscience, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/anro/catalysts

```bibtex
@misc{secapidev_companies_anro_catalysts_20261116,
  title        = {ANRO catalysts: Alto Neuroscience, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/anro/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_anro_catalysts_20261116","title":"ANRO catalysts: Alto Neuroscience, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/anro/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
